X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.bayer.com/media/en-us/new-kerendia-finerenone-data-show-impact-of-early-albuminuria-reduction-in-patients-with-chronic-kidney-disease-and-type-2-diabetes/
https://www.bayer.com/media/en-us/bayer-to-present-new-data-on-kerendia-finerenone-from-comprehensive-clinical-trial-program-in-chronic-kidney-disease-and-type-2-diabetes/
https://www.bayer.com/media/en-us/kerendia-finerenone-granted-expanded-indication-in-china-for-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes/
https://www.fiercepharma.com/pharma/rough-quarter-bayers-duo-nubeqa-kerendia-continue-excel
https://www.ema.europa.eu/en/documents/overview/kerendia-epar-medicine-overview_en.pdf
https://endpts.com/bayer-starts-work-on-43m-expansion-of-otc-manufacturing-site-in-pennsylvania/
https://www.pharmafile.com/news/740750/scottish-medicines-consortium-approves-bayer-s-kerendia-nhs-scotland
https://www.fiercepharma.com/pharma/esc-bayers-kerendia-can-cut-risk-sudden-cardiac-arrest-those-chronic-kidney-disease
https://media.bayer.com/baynews/baynews.nsf/id/New-indicate-positive-effects-Kerendia-finerenone-mortality-patients-chronic-kidney-disease-2?Open&parent=news-overview-category-search-en&ccm=020
http://www.pharmafile.com/news/610879/mhra-authorisation-new-treatment-chronic-kidney-disease-associated-diabetes
https://www.contractpharma.com/contents/view_breaking-news/2021-12-20/evofem-biosciences-orion-biotechnology-enter-ob-002-alliance/?widget=listSection
https://www.fiercepharma.com/pharma/bayer-s-kerendia-sglt2-combo-showing-exceeds-expectation-heart-disease-diabetes-pharma-chief
https://www.businesswire.com/news/home/20211027005538/en/Bayer-to-present-new-analyses-adding-to-the-depth-of-knowledge-on-the-cardiovascular-and-renal-outcomes-of-KERENDIA%C2%AE-finerenone
http://www.pharmafile.com/news/589620/bayer-phase-iii-trial-results-prove-positive-diabetes-patients
https://www.fiercepharma.com/pharma/a-month-after-its-initial-approval-kerendia-shows-its-worth-as-a-complementary-treatment
https://www.escardio.org/The-ESC/Press-Office/Press-releases/Finerenone-improves-outcomes-in-patients-with-mild-to-moderate-kidney-disease-and-diabetes
https://www.fiercepharma.com/pharma/kidney-medicine-bayer-touts-kerendia-potential-as-pharma-swings-back-to-growth
https://www.prnewswire.com/news-releases/patient-impact-statement-fda-approval-of-kerendia-to-help-slow-kidney-disease-and-failure-associated-with-type-2-diabetes-301334966.html
http://www.pharmatimes.com/news/bayers_kerendia_approved_in_the_us_to_slow_ckd_in_type_2_diabetes_patients_1373097
https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease
https://www.expresspharma.in/bayer-gets-us-fda-nod-for-kerendia-finerenone-to-treat-ckd-associated-with-type-2-diabetes/
https://endpts.com/bayer-wins-priority-review-for-ckd-program-finerenone-after-phiii-data-showed-a-delay-in-disease-progression/
https://www.fiercebiotech.com/biotech/aha-bayer-s-finerenone-helps-kidney-heart-disease-patients-regardless-medical-history
https://www.fiercebiotech.com/biotech/bayer-s-heart-failure-pill-hinders-kidney-disease-heart-disease-phase-3
Market Place
Share 
